Using FDG-PET Acquired During the Course of Radiation Therapy to Individualize Adaptive Radiation Dose Escalation in Patients With Non-Small Cell Lung Cancer
- Patients must have FDG-avid and pathologically proven non-small cell lung cancer. If
pathology not definitive, the patient needs to have a clinically diagnosed non-small
cell lung cancer, which is also FDG-avid.
- Patients must be 18 years of age or older.
- Patients must have Karnofsky performance score > 60.
- Patients must have clinical AJCC Stage I-IIIB, with unresectable or inoperable
- Patients must have no evidence of a malignant pleural or pericardial effusion
- Patients must have hemoglobin > 10 gm/dl. Transfusions or medications may be used to
achieve this criterion.
- Patients must have reasonable organ and marrow functions as defined below if
chemotherapy is considered:
- WBC > 3,000/mm3.
- absolute neutrophil count ≥ 1,500/mm3.
- platelets > 100,000/mm3
- total bilirubin ≤ 3.0 mg/dl.
- AST (SGOT) and ALT (SGPT) < 4 X institutional upper limit of normal.
- creatinine ≤ 2.0 mg/dl.
- Patients must not have serious intercurrent diseases per the judgment of the treating
- Patient must be willing to use effective contraception if female with reproductive
- Patients must be informed of the investigational nature of this study and given
written informed consent in accordance with institutional and federal guidelines.
- Patients with any component of small cell lung carcinoma are excluded from this
- Prior radiotherapy to the thorax such that composite radiation would significantly
overdose critical structures, either per estimation of the treating radiation
oncologist or defined by failure to meet normal tissue tolerance constraints.
- Pregnant women are excluded from this study because radiation has the potential for
teratogenic or abortifacient effects.
- Prisoners are excluded for this study.